Ionis Pharmaceuticals announced that the European Commission has approved its antisense therapy DAWNZERA (donidalorsen) for the routine prevention of hereditary angioedema (HAE) in adults and adolescents aged 12 and older. The approval, granted on January 21 2026, follows a positive opinion from the Committee for Medicinal Products for Human Use and is based on robust Phase 3 OASIS‑HAE and OASISplus data showing a 94 % reduction in mean monthly attack rates at one year.
The U.S. FDA had already approved DAWNZERA in August 2025, and the drug is now available in the EU through an exclusive partnership with Otsuka Pharmaceutical Co., Ltd. Under the agreement, Ionis will receive a $15 million milestone payment and tiered royalties of up to 30 % on net product sales, providing a clear revenue upside as the drug enters the European market.
DAWNZERA’s self‑administration via autoinjector every four or eight weeks offers a patient‑friendly alternative to existing therapies such as lanadelumab and C1‑esterase inhibitors. The dosing schedule and ease of use position the drug to capture a share of the estimated €1.5 billion‑plus HAE market in Europe, where the prevalence is about 15,000 patients. Ionis’s strategy of independent commercialization is reinforced by this launch, which expands its portfolio beyond the U.S. and strengthens its competitive stance against established HAE treatments.
Management highlighted the significance of the approval, noting that DAWNZERA is the first RNA‑targeted therapy for HAE and could become the prophylactic therapy of choice for many patients across the EU. The milestone payment and royalty structure provide a predictable revenue stream, while the patient‑convenient dosing schedule is expected to drive adoption among clinicians and payers, supporting long‑term growth in the hereditary angioedema segment.
The EU approval marks a key milestone in Ionis’s transition to a fully integrated commercial‑stage biotechnology company. By launching DAWNZERA in Europe, Ionis not only expands its addressable market but also demonstrates the commercial viability of its antisense platform, enhancing investor confidence in the company’s pipeline and independent launch capabilities.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.